Can a daily pill tame a hidden heart risk?

NCT ID NCT07767513

NEW Not yet recruiting Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial tests whether an oral drug called HRS-5346 can safely lower elevated lipoprotein(a) — a genetic risk factor for heart attacks and strokes — in adults at high cardiovascular risk. Participants will take one of two doses of the drug or a placebo for 12 weeks, and researchers will measure changes in their Lp(a) levels. The goal is to find the right dose for a potential future treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-5346, an oral drug being tested to lower elevated lipoprotein(a) levels
What this could lead to: If successful, this could lead to a new oral treatment to reduce cardiovascular risk in people with high Lp(a) levels.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not confirm effectiveness or safety. The drug may not produce the desired reduction in Lp(a) or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIPOPROTEIN DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIPOPROTEIN DISORDER

Contacts and locations

Locations

West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.